The problem of new uses.
Eisenberg
Rebecca S
RS
University of Michigan Law School, USA.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D002319:Cardiovascular System / Q000187:drug effects; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D010330:Patents as Topic / Q000331:legislation & jurisprudence; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use; D014342:Truth Disclosure; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib